CUBE vs DMAC
CubeSmart (CUBE) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
DMAC does not have a complete income-statement cache yet.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the CUBE and DMAC stock pages for the full models.
Not investment advice.